Amgen (AMGN) Q2 FY26 earnings call

Amgen delivered robust Q2 FY26 results, driven by strong performance across its diversified portfolio of innovative medicines and biosimilars, particularly its six key growth drivers. The company raised its full-year revenue and non-GAAP EPS guidance, reflecting confidence in its pipeline advancements, including MariTide and Olpasiran, and continued operational execution. Strategic investments in R&D and manufacturing capacity are aimed at sustaining long-term growth well into the next decade.